A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer

International Journal of Radiation Oncology Biology Physics

Volumn 83, Issue 4, 2012, Pages 1113-1119

  Della Vittoria Scarpati, Giuseppina ^a   Falcetta, Francesca ^b   Carlomagno, Chiara ^a   Ubezio, Paolo ^b   Marchini, Sergio ^b   De Stefano, Alfonso ^a   Singh, Vijay Kumar ^c   D'Incalci, Maurizio ^b   De Placido, Sabino ^a   Pepe, Stefano ^d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c Laboratory of Cancer Genomics   (Italy)

^d UNIVERSITY OF SALERNO   (Italy)

Author keywords

miRNA; Predictive factors; Preoperative chemoradiotherapy; Rectal cancer

Indexed keywords

COLORECTAL CANCER; COMPLETE RESPONSE; MICROARRAY ANALYSIS; MICRORNAS; MIRNA; NEOADJUVANT CHEMORADIOTHERAPY; NON-CODING RNAS; PATHOLOGIC RESPONSE; PATHOLOGICAL RESPONSE; PREDICTIVE FACTORS; Q-RT-PCR; RECTAL CANCER; REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

BIOPSY; CHEMORADIOTHERAPY; POLYMERASE CHAIN REACTION; RNA;

DISEASES;

CAPECITABINE PLUS OXALIPLATIN; MICRORNA;

ADJUVANT CHEMORADIOTHERAPY; ADVANCED CANCER; ARTICLE; CANCER PROGNOSIS; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; RECTUM BIOPSY; RECTUM CANCER; RECTUM SURGERY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR REGRESSION; UPREGULATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOPSY; CHEMORADIOTHERAPY, ADJUVANT; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MICROARRAY ANALYSIS; MICRORNAS; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; RECTAL NEOPLASMS; RECTUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY;

EID: 84862705778     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.09.030     Document Type: Article

References (23)

1. Aslam MI, Taylor K, Pringle JH, et al. MicroRNAs are novel biomarkers of colorectal cancer. Br J Surg 2009;96:702-710.
2. Faber C, Kirchner T, Hlubek F. The impact of microRNAs on colorectal cancer. Virchows Arch 2009;454:359-367.
3. Shenouda SK, Alahari SK. MicroRNA function in cancer: Oncogene or a tumor suppressor? Cancer Metastasis Rev 2009;28:369-378.
4. Michael MZ, van Holst SMOC, Pellekaan NG, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003;1:882-891.
5. Bandres E, Cubedo E, Agirre X, et al. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006;5:29.
6. Slaby O, Svoboda M, Michalek J, et al. MicroRNAs in colorectal cancer: Translation of molecular biology into clinical application. Mol Cancer 2009;8:102.
7. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299:425-436.
8. Schepeler T, Reinert JT, Ostenfeld MS, et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008;68: 6416-6424.
9. Xi Y, Formentini A, Chien M, et al. Prognostic values of microRNAs in colorectal cancer. Biomark Insights 2006;2:113-121.
10. Graziano F, Canestrari E, Loupakis F, et al. Genetic modulation of the Let-7 microRNA binding to KRAS 30-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab- irinotecan. Pharmacogenomics J 2010;10:458-464.
11. Hummel R, Hussej DJ, Haier J. MicroRNAs: Predictors and modifiers of chemo- and radiotherapy in different tumor types. Eur J Cancer 2010;46:298-311.
12. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
13. Suarez J, Vera R, Balén E, et al. Pathologic response assessed by Mandard grade is a better prognostic factor than downstaging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer. Colorectal Dis 2007;10:563-568.
14. Carlomagno C, Pepe S, D'Armiento FP, et al. Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Oncology 2010;78:369-375.
15. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer 1994;73:2680-2686.
16. Carlomagno C, Farella A, Bucci L, et al. Neoadjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: A phase II study. Ann Oncol 2009;20:906-912.
17. Marchini S, Cavalieri D, Fruscio R, et al. Association between miR- 200c and the survival of patients with stage I epithelial ovarian cancer: A retrospective study of two independent tumour tissue collections. Lancet Oncol 2011;12:273-285.
18. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Stat Soc B 1995;57:289-300.
19. Svoboda M, Izakovicova HL, Sefr R, et al. Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer. Int J Oncol 2008;33:541-547.
20. Nakajima G, Hayashi K, Xi Y, et al. Non-coding MicroRNAs hsalet- 7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics Proteomics 2006;3:317-324.
21. Eitan R, Kushnir M, Lithwick-Yanai G, et al. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol 2009;114:253-259.
22. Jang N, Kaur S, Volinia S, et al. MiscoRNA microarray indentifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 2008;68:10307-10314.
23. Galluzzi L, Morselli E, Vitale I, et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010;70: 1793-1803.